Annual FCF
-$21.07 M
-$3.08 M-17.12%
December 31, 2023
Summary
- As of February 8, 2025, ONCY annual free cash flow is -$21.07 million, with the most recent change of -$3.08 million (-17.12%) on December 31, 2023.
- During the last 3 years, ONCY annual FCF has fallen by -$4.58 million (-27.78%).
- ONCY annual FCF is now -5548.49% below its all-time high of -$373.10 thousand, reached on December 31, 1999.
Performance
ONCY Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
N/A
September 30, 2024
Summary
- ONCY quarterly free cash flow is not available.
Performance
ONCY Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM FCF
N/A
September 30, 2024
Summary
- ONCY TTM free cash flow is not available.
Performance
ONCY TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
ONCY Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -17.1% | - | - |
| 3 y3 years | -27.8% | - | - |
| 5 y5 years | -127.1% | - | - |
ONCY Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -17.1% | at low | ||||
| 5 y | 5-year | -40.4% | at low | ||||
| alltime | all time | -5548.5% | +38.7% |
Oncolytics Biotech Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$21.07 M(+17.1%) | -$4.44 M(-1.9%) | -$21.07 M(-0.8%) |
| Sep 2023 | - | -$4.52 M(-28.5%) | -$21.25 M(+7.5%) |
| Jun 2023 | - | -$6.33 M(+9.3%) | -$19.77 M(+5.0%) |
| Mar 2023 | - | -$5.79 M(+25.5%) | -$18.82 M(+4.6%) |
| Dec 2022 | -$17.99 M(-0.7%) | -$4.61 M(+51.8%) | -$17.99 M(-3.0%) |
| Sep 2022 | - | -$3.04 M(-43.5%) | -$18.55 M(+0.9%) |
| Jun 2022 | - | -$5.38 M(+8.5%) | -$18.39 M(-1.6%) |
| Mar 2022 | - | -$4.96 M(-4.1%) | -$18.69 M(+3.1%) |
| Dec 2021 | -$18.12 M(+9.9%) | -$5.17 M(+79.9%) | -$18.12 M(+5.6%) |
| Sep 2021 | - | -$2.88 M(-49.4%) | -$17.16 M(-10.6%) |
| Jun 2021 | - | -$5.68 M(+29.3%) | -$19.19 M(+7.0%) |
| Mar 2021 | - | -$4.39 M(+4.3%) | -$17.93 M(+8.7%) |
| Dec 2020 | -$16.49 M(+9.9%) | -$4.21 M(-14.1%) | -$16.49 M(-6.8%) |
| Sep 2020 | - | -$4.90 M(+10.9%) | -$17.70 M(+8.6%) |
| Jun 2020 | - | -$4.42 M(+49.4%) | -$16.30 M(+5.7%) |
| Mar 2020 | - | -$2.96 M(-45.5%) | -$15.42 M(+2.7%) |
| Dec 2019 | -$15.01 M(+61.7%) | -$5.42 M(+55.0%) | -$15.01 M(+15.3%) |
| Sep 2019 | - | -$3.50 M(-1.1%) | -$13.02 M(+6.8%) |
| Jun 2019 | - | -$3.54 M(+38.9%) | -$12.19 M(+49.6%) |
| Mar 2019 | - | -$2.55 M(-25.8%) | -$8.15 M(-12.2%) |
| Dec 2018 | -$9.28 M(-19.8%) | -$3.43 M(+28.5%) | -$9.28 M(+15.5%) |
| Sep 2018 | - | -$2.67 M(-628.0%) | -$8.04 M(-4.0%) |
| Jun 2018 | - | $506.00 K(-113.7%) | -$8.37 M(-31.8%) |
| Mar 2018 | - | -$3.68 M(+68.4%) | -$12.27 M(+6.0%) |
| Dec 2017 | -$11.57 M(+22.6%) | -$2.19 M(-27.2%) | -$11.57 M(-4.9%) |
| Sep 2017 | - | -$3.01 M(-11.4%) | -$12.17 M(+6.4%) |
| Jun 2017 | - | -$3.39 M(+13.8%) | -$11.43 M(+11.9%) |
| Mar 2017 | - | -$2.98 M(+7.1%) | -$10.22 M(+8.3%) |
| Dec 2016 | -$9.44 M(-20.4%) | -$2.79 M(+22.8%) | -$9.44 M(-8.2%) |
| Sep 2016 | - | -$2.27 M(+3.9%) | -$10.29 M(+4.7%) |
| Jun 2016 | - | -$2.18 M(-0.9%) | -$9.83 M(-17.0%) |
| Mar 2016 | - | -$2.20 M(-39.4%) | -$11.84 M(-0.2%) |
| Dec 2015 | -$11.86 M(-33.9%) | -$3.63 M(+100.6%) | -$11.86 M(+7.4%) |
| Sep 2015 | - | -$1.81 M(-56.8%) | -$11.05 M(-17.7%) |
| Jun 2015 | - | -$4.19 M(+88.1%) | -$13.42 M(-8.0%) |
| Mar 2015 | - | -$2.23 M(-20.9%) | -$14.58 M(-18.8%) |
| Dec 2014 | -$17.96 M(-25.1%) | -$2.82 M(-32.7%) | -$17.96 M(-8.4%) |
| Sep 2014 | - | -$4.18 M(-22.0%) | -$19.61 M(-9.2%) |
| Jun 2014 | - | -$5.36 M(-4.4%) | -$21.59 M(+1.7%) |
| Mar 2014 | - | -$5.61 M(+25.7%) | -$21.23 M(-11.5%) |
| Dec 2013 | -$23.98 M(-30.3%) | -$4.46 M(-27.6%) | -$23.98 M(-8.3%) |
| Sep 2013 | - | -$6.16 M(+23.4%) | -$26.15 M(-7.1%) |
| Jun 2013 | - | -$5.00 M(-40.2%) | -$28.15 M(-17.8%) |
| Mar 2013 | - | -$8.36 M(+26.1%) | -$34.23 M(-0.5%) |
| Dec 2012 | -$34.39 M(+49.2%) | -$6.63 M(-18.7%) | -$34.39 M(-1.8%) |
| Sep 2012 | - | -$8.16 M(-26.4%) | -$35.03 M(+4.4%) |
| Jun 2012 | - | -$11.09 M(+30.1%) | -$33.55 M(+21.3%) |
| Mar 2012 | - | -$8.52 M(+17.2%) | -$27.65 M(+19.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | -$23.06 M(+32.4%) | -$7.27 M(+8.9%) | -$23.06 M(+18.4%) |
| Sep 2011 | - | -$6.68 M(+28.8%) | -$19.47 M(+11.0%) |
| Jun 2011 | - | -$5.18 M(+32.1%) | -$17.53 M(+5.7%) |
| Mar 2011 | - | -$3.93 M(+6.6%) | -$16.59 M(-4.7%) |
| Dec 2010 | -$17.41 M(+23.1%) | -$3.68 M(-22.4%) | -$17.41 M(+4.2%) |
| Sep 2010 | - | -$4.74 M(+11.8%) | -$16.71 M(+12.5%) |
| Jun 2010 | - | -$4.24 M(-10.7%) | -$14.86 M(-5.2%) |
| Mar 2010 | - | -$4.75 M(+59.2%) | -$15.68 M(+10.8%) |
| Dec 2009 | -$14.15 M(-2.4%) | -$2.98 M(+3.4%) | -$14.15 M(+3.8%) |
| Sep 2009 | - | -$2.88 M(-43.0%) | -$13.63 M(-12.5%) |
| Jun 2009 | - | -$5.06 M(+56.9%) | -$15.57 M(+7.5%) |
| Mar 2009 | - | -$3.22 M(+30.8%) | -$14.49 M(-0.1%) |
| Dec 2008 | -$14.50 M(+6.8%) | -$2.46 M(-48.9%) | -$14.50 M(-0.8%) |
| Sep 2008 | - | -$4.83 M(+21.4%) | -$14.62 M(+9.4%) |
| Jun 2008 | - | -$3.98 M(+23.0%) | -$13.37 M(-0.2%) |
| Mar 2008 | - | -$3.23 M(+25.0%) | -$13.39 M(-1.3%) |
| Dec 2007 | -$13.58 M(+26.3%) | -$2.59 M(-27.5%) | -$13.58 M(-0.7%) |
| Sep 2007 | - | -$3.57 M(-11.0%) | -$13.68 M(+6.3%) |
| Jun 2007 | - | -$4.01 M(+17.4%) | -$12.87 M(+9.0%) |
| Mar 2007 | - | -$3.41 M(+27.0%) | -$11.81 M(+9.9%) |
| Dec 2006 | -$10.75 M(+17.1%) | -$2.69 M(-2.5%) | -$10.75 M(+10.6%) |
| Sep 2006 | - | -$2.76 M(-6.4%) | -$9.72 M(-8.7%) |
| Jun 2006 | - | -$2.95 M(+25.1%) | -$10.65 M(+7.3%) |
| Mar 2006 | - | -$2.35 M(+41.7%) | -$9.93 M(+8.2%) |
| Dec 2005 | -$9.18 M(+29.0%) | -$1.66 M(-55.0%) | -$9.18 M(+15.9%) |
| Sep 2005 | - | -$3.69 M(+66.1%) | -$7.92 M(+10.1%) |
| Jun 2005 | - | -$2.22 M(+38.4%) | -$7.20 M(-6.0%) |
| Mar 2005 | - | -$1.60 M(+296.0%) | -$7.66 M(+7.6%) |
| Dec 2004 | -$7.11 M(+51.3%) | -$405.20 K(-86.3%) | -$7.11 M(-13.2%) |
| Sep 2004 | - | -$2.96 M(+10.5%) | -$8.20 M(+33.0%) |
| Jun 2004 | - | -$2.68 M(+152.4%) | -$6.16 M(+32.4%) |
| Mar 2004 | - | -$1.06 M(-28.6%) | -$4.66 M(-1.0%) |
| Dec 2003 | -$4.70 M(-11.1%) | -$1.49 M(+59.9%) | -$4.70 M(+19.3%) |
| Sep 2003 | - | -$931.30 K(-20.7%) | -$3.94 M(-37.8%) |
| Jun 2003 | - | -$1.17 M(+5.8%) | -$6.34 M(+39.2%) |
| Mar 2003 | - | -$1.11 M(+52.4%) | -$4.55 M(-14.0%) |
| Dec 2002 | -$5.29 M(+68.7%) | -$728.10 K(-78.1%) | -$5.29 M(-3.3%) |
| Sep 2002 | - | -$3.32 M(-645.0%) | -$5.47 M(+84.8%) |
| Jun 2002 | - | $609.80 K(-132.9%) | -$2.96 M(-29.6%) |
| Mar 2002 | - | -$1.85 M(+103.8%) | -$4.21 M(+34.1%) |
| Dec 2001 | -$3.14 M(+45.3%) | -$908.80 K(+12.0%) | -$3.14 M(+10.4%) |
| Sep 2001 | - | -$811.50 K(+27.6%) | -$2.84 M(-7.7%) |
| Jun 2001 | - | -$636.20 K(-18.6%) | -$3.08 M(+11.0%) |
| Mar 2001 | - | -$781.50 K(+27.4%) | -$2.78 M(+28.5%) |
| Dec 2000 | -$2.16 M(+478.8%) | -$613.40 K(-41.5%) | -$2.16 M(+39.7%) |
| Sep 2000 | - | -$1.05 M(+216.3%) | -$1.55 M(+211.2%) |
| Jun 2000 | - | -$331.70 K(+100.8%) | -$496.90 K(+200.8%) |
| Mar 2000 | - | -$165.20 K | -$165.20 K |
| Dec 1999 | -$373.10 K | - | - |
FAQ
- What is Oncolytics Biotech annual free cash flow?
- What is the all time high annual FCF for Oncolytics Biotech?
- What is Oncolytics Biotech annual FCF year-on-year change?
- What is the all time high quarterly FCF for Oncolytics Biotech?
- What is the all time high TTM FCF for Oncolytics Biotech?
What is Oncolytics Biotech annual free cash flow?
The current annual FCF of ONCY is -$21.07 M
What is the all time high annual FCF for Oncolytics Biotech?
Oncolytics Biotech all-time high annual free cash flow is -$373.10 K
What is Oncolytics Biotech annual FCF year-on-year change?
Over the past year, ONCY annual free cash flow has changed by -$3.08 M (-17.12%)
What is the all time high quarterly FCF for Oncolytics Biotech?
Oncolytics Biotech all-time high quarterly free cash flow is $609.80 K
What is the all time high TTM FCF for Oncolytics Biotech?
Oncolytics Biotech all-time high TTM free cash flow is -$165.20 K